A pyrazolopyridine HBSC11 was previously identified as a novel inhibitor of human La protein with anti-hepatitis B virus (HBV) activity. However, the underlying mechanism(s) of HBV inhibition by HBSC11 remains unclear. This study aimed to examine the regulation of microRNA (miRNA) by HBSC11 in HBV-transformed human hepatoma 
atypical RRM and nuclear localization sequence (NLS). 4 Mammalian La protein has been shown to specifically bind to a predicted stem-loop in HBV RNA (1275-1291 nt) and thus stabilize the viral RNA. 5 In addition, the RRM-2 and RRM-3 are separately required for the binding, indicating a cooperative function of these two RRMs. 6 More recently, it has been reported that inhibition of human La protein by RNA interference downregulates the expression of HBV mRNA and protein. 7 Therefore, La protein is an important target for inhibiting HBV infection.
In our previous studies, a novel inhibitor of human La protein, a pyrazolopyridine HBSC11, with anti-HBV activity, was discovered by structure-based virtual screening and in vitro evaluation. 8, 9 microRNAs (miRNAs) are an abundant class of small non-coding RNA molecules, containing about 21-23 nucleotides. miRNA duplex was generated by Dicer cleavage of the double-stranded region of a 60-70-nt RNA hairpin precursor. The regulatory functions of miRNAs are accomplished through binding to the consensus sequences of target gene mRNA and activation of the RNA-induced silencing complex (RISC), 10, 11 which degrades mRNA or inhibits mRNA translation. 12, 13 It has been demonstrated that miRNAs play an significant role in cell proliferation, 14 growth, 15 and apoptosis, 16 as well as viral replication. 17 Notably, La protein has been reported to act as a pre-miRNA-binding protein that regulates miRNA processing in vitro. 18 To further investigate the potential mechanism and key regulatory factor of HBSC11-medicated inhibition of HBV, miRNA microarray analysis was performed in the stably HBV-expressing human org/microrna/home.do), miRDB (http://mirdb.org/miRDB/), and probability of interaction by target accessibility (PITA) (https://genie.
weizmann.ac.il/pubs/mir07/mir07_prediction.html) with human selected as the species.
| Bioinformatic analyses of predicted target genes
After target prediction of the differentially expressed miRNAs, Gene
Ontology (GO) and Kyoto Encyclopedia of genes and genomes (KEGG) pathway analyses was performed. The above predicted miRNA target genes were input into the online DAVID database.
These bioinformatics resources are able for utilizing the GO database to provide functional information about gene products and to describe functions through the adoption of domain-specific ontologies, particularly suitable for functional analysis of miRNAs.
Further, Fisher's exact test and chi-square test were applied to the GO annotations to calculate the P values. Finally, the false discovery rate (FDR) was assessed by conducting multiple comparisons of the null hypothesis tests. The smaller the P value, the more significant the function of target genes in the GO enrichment analysis. In addition, the target genes input into the online DAVID bioinformatics resources were linked to the KEGG pathway database to create the KEGG pathway annotations. The coded genes in the module were used as target genes and compared to reference genes in the KEGG pathways. Statistical analyses were similar to the analyses in GO annotation analysis.
| Statistical analysis
The data are expressed as mean ± standard deviation of three independent experiments with three biological replicates. Statistical differences were identified by Student's t-test using SPSS 17.0 software (SPSS, Inc., Chicago, IL), and a significance difference was defined as P < 0.05 with miRNA expression showing ≥2.0-fold upregulation or ≤0.5-fold downregulation. Additionally, the Benjamini-Hochberg FDR was used for multiple-testing correction (cutoff was 0.05). P-values <0.05 (two-tailed) were considered statistically significant.
3 | RESULTS
| miRNAs differentially expressed after HBSC11 treatment
Using the human miRNA (8 × 60 K) array, three miRNAs (hsa-miR-3912-5p, hsa-miR-6793-5p, and hsa-miR-7159-5p) were identified significantly upregulated by HBSC11 treatment in HepG2.2.15 cells.
The fold changes in expression were 21.2329 (P = 0.0078), 16.3439 (P = 0.0029), and 45.3816 (P = 0.0026), respectively (Table 1) . To directly view the differentially expressed miRNAs, a scatter diagram of miRNA expression was plotted ( Figure 1A ). The scatter plot showed the genes that were 2-fold upregulated and downregulated (red and green dots, respectively) and filtered the genes with a fold-change value between 0.5-and 2-fold (black dots). However, considering that P values were not considered in the scatter plot, the further statistical analysis of miRNA expression was performed by volcano scatter plot analysis ( Figure 1B) . The red point in the plot represents the genes that were differentially expressed with statistical significance. As shown in Figure 1B , there were three miRNAs with fold changes >2 and P values <0.05. The heat map ( Figure 1C ) shows distinctive expression patterns for specific miRNAs associated with the HBSC11-treated group and DMSO control group. Specifically, hsa-miR-3912-5p, hsa-miR-6793-5p, and hsa-miR-7159-5p were up-regulated in the HBSC11-treated group.
| Validation of miRNA expression by qRT-PCR
To confirm the miRNA array data, qRT-PCR was used to meausre the expression of the three miRNAs. As shown in Figure 2 , the three miRNAs were validated to be upregualted by HBSC11 treatment in 
| KEGG pathways of target genes involved
KEGG is a pathway-based analysis to explore the biological functions of genes. Further KEGG analysis was carried out to explore the pathways of candidate target genes with which the three miRNAs may be associated. As shown in Figure 4 , the target genes were primarily enriched in the KEGG pathways of ubiquitin-mediated proteolysis, transforming growth factor (TGF)-β signaling, Wnt signaling, and p53 signaling.
| DISCUSSION
HBSC11 is a pyrazolopyridine that has been identified as a novel inhibitor of human La protein. Our earlier study using structure-based virtual screening and in vitro evaluation showed that HBSC11 exerted great inhibitory effects on HBV replication. 8 This study revealed that HBSC11 upregulated the expression of three miRNAs, hsa-miR-3912-5p, hsa-miR-6793-5p, and hsa-miR-7159-5p in HepG2.2.15 cells.
These miRNAs target a pattern of genes that are widely enriched in several pathways involved in regulating HBV replication and associated disease progression. to inhibit HBV replication via NDRG3. 23 Loss of miR-122 expression in patients with HBV enhanced viral replication through cyclin G (1)-modulated P53 activity. 24 Later, HBV mRNA was reported to inhibit miR-122 expression and thus upregulated PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. 25 MiR-15a/miR-16-1 were also identified to be downregulated by HBV RNA in hepatocytes. 26 In addition, liver levels of hsa-miR-125a-5p have been correlated with liver HBV DNA level FIGURE 3 GO analysis based on miRNA target genes. The vertical axis is the GO category, and the horizontal axis is the enrichment score, which is equal to −log10 (P value) that represents the significant level of GOs. GO: Gene ontology. P < 0.05 was considered statistically significant FIGURE 4 KEGG analysis based on miRNA target genes. The vertical axis is the pathway category, and the horizontal axis is the enrichment of pathways, which is equal to −log10 (P value) that represents the significant level of GOs. KEGG: Kyoto Encyclopedia of Genes and Genomes; TGF-β: transforming growth factor beta; p53: tumor protein p53. P < 0.05 was considered statistically significant and fibrosis score, implicating this miRNA as an independent predictor of disease progression. 27 In contrast, miR-125b inhibits HBV expression in vitro through targeting of the SCNN1A gene. 28 As for miRNA biogenesis, typically, the primary miRNA (pri-miRNA) transcripts are processed by the nuclear Drosha complex into ∼70-nt stem-loop pre-miRNAs. These pre-miRNAs are further cleaved by the cytoplasmic Dicer complex into mature miRNAs. Recently, La protein was further shown to recognize the characteristic stem-loop structure of pre-miRNAs, of which the majority lack a 3′ UUU terminus. 18 As such, La protein may act as a global regulator of miRNA expression. Considering the binding sites of HBSC11 to La locate within this region, it is reasonable to assume that HBSC11 will affect processing of certain miRNAs.
The present study showed that the La-specific inhibitor HBSC11 34 To our surprise, La and La-related protein are closely connected to liver cancer. 35, 36 Therefore, it is of clinical significance to study whether La protein plays a role in HBV-related liver cancer via regulation of HBV expression. In our previous systematic analysis, TNFSF10, CCND1, and Bcl2 were also included in the overlapping target genes of La, CK2, and HBV. 37 Therefore, La inhibitor HBSC11 may regulate these genes and thus suppress HBV replication.
Further bioinformatics GO analysis showed that these target antoantigen was shown to bind the X-linked inhibitor of apoptosis (XIAP) IRES element, facilitating ribosome recruitment and XIAP translation. 40 In addition, La protein is also involved in the activation of mdm2 mRNA translation by BCR/ABL, 41 and enhanced translation of BiP mRNA 42 and 5′-terminal oligopyrimidine (5′-TOP) mRNAs. 43 Therefore, the La inhibitor HBSC11 may regulate the translation of these genes via the three upregulated miRNAs. Further KEGG analysis revealed that the target genes of the three miRNAs were primarily enriched in the KEGG pathways, including ubiquitinmediated proteolysis, TGF-β signaling, Wnt signaling, and p53
signaling. TGF-β has been shown to induce expression at the mRNA level of multiple TGF-β/BMP pathway genes, possibly governed by TGF-β-induced miRNA expression (eg, hsa-miR-125a-5p), thus decreasing both HBV mRNA and DNA expression. 44 Most recently, TGF-β was found to trigger HBV cccDNA degradation through AIDdependent deamination. 45 In summary, our study showed that the novel La inhibitor 
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